Targeted Therapies in Bladder Cancer
Matthew D. Galsky, MD, discusses targeted therapy treatments for bladder cancer.
Matthew D. Galsky, MD, assistant professor of medicine, Department of Medicine, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, director, Genitourinary Medical Oncology, Tisch Cancer Institute at Mount Sinai Medical Center, discusses targeted therapy treatments for bladder cancer.
Clinical Pearls:
- Targeting tumor angiogenesis and HSP27 could prove to be promising approaches in the treatment of bladder cancer
- While studies that are looking at anti-angiogenic approaches in bladder cancer have shown that the majority of patients do not respond, some patients did respond
- The combination of conventional chemotherapy and anti-angiogenic drugs is difficult to give because they have some overlapping side effects
- Targeting VEGF with an antibody might be more promising in terms of the ability to deliver both drugs effectively without overlapping toxicities
- A study that is exploring gemcitabine and cisplatin with or without bevacizumab should establish a role for this class of drugs in the treatment of bladder cancer
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
